E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Juvenile Idiopathic Arthrithis (JIA) |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Information not present in EudraCT |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary objective To test the primary hypothesis:
1. PAIN: Patient will not grade his/her pain higher during joint injection (procedural pain), than before the procedure (base line of pain). This is measured by Coloured Analogue Scale (CAS) by the patient.
2. TOTAL IMPRESSION: Patient state that they prefer Nitrous Oxide (50%N2O/50%O2) during a future joint injection, to receive adequate analgesia and sedation. This is measured by asking the patient immediately after the procedure and after one week, endpoint yes – no. Each patient will also grade his/her feelings before, during and after procedure by Facial Analogue Scale (FAS) immediately after the procedure and after one week.
|
|
E.2.2 | Secondary objectives of the trial |
To test secondary hypothesis:
1. TOTAL IMPRESSION: Nitrous Oxide (50%N2O/50%O2) is the method for receiving analgesia and sedation that the patient believes is the best during joint injections, according to those patients whom have tried other methods for receiving analgesia and sedation during joint injections. 2. FASTING TIME: No increase of presence of nausea and vomiting for those patients that have two hours fasting time versus those patients that have four hours of fasting time.
Patients who are subject to a second treatment with joint injections during the course of the study will be asked to test Guided Imagery for analgesia. Nitrous Oxide (50%N2O/50%O2) is then told by the patient to be better than Guided Imagery regarding analgesia, when we ask the patient immediatly after procedure and after one week.
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. ASA 1 and ASA 2 patients with an acute phase of of JIA 2. Age 5-18 years 3. Written informed consent by patient and/or parent. The doctor have initially asked and informed about participation in the study if there are no contra-indications
|
|
E.4 | Principal exclusion criteria |
1. More than 3 joints need intra articular cortisone injection 2. Language difficulties 3. Present infection 4. Psychologically unstable patients (for example psychogical trauma, bad experience from war etc) 5. Clinically significant heart/lung disease 6. Pathological B12-status 7. Affected CNS 8. Porphyria
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary variables: 1. PAIN Patient will grade his/her pain before the procedure (baseline of pain) and during joint injection (preocedural pain), by Coloured Analogue Scale (CAS). Endpoints are from “no pain” – “worst pain ever experienced”
2. TOTAL IMPRESSION Patients will be asked immediately after the procedure, and after one week if they prefer Nitrous Oxide (50%N2O/50%O2) during a future joint injection, to receive adequate analgesia and sedation (endpoint: yes – no). Each patient will also grade his/her feelings before, during and after procedure by Facial Analogue Scale (FAS) immediately after the procedure and after one week.
Secondary variables: 1. PREFERENCE Patients, whom have tried other methods for receiving analgesia and sedation during joint injections, will be asked immediately after the procedure, and after one week about their preferred method for receiving analgesia and sedation during joint injections.
Patients who are subject to a second treatment with joint injections during the course of the study will be asked to test Guided Imagery for analgesia. Patients who agree to this treatment will be asked immediately after the procedure, and after one week about their preference for Nitrous Oxide (50%N2O/50%O2) or Guided Imagery as the method for receiving analgesia and sedation during joint injections.
2. FASTING TIME Presence of nausea and vomiting for those patients that have two hours fasting time versus those patients that have four hours of fasting time will be measured by asking and observing the patient during procedure, and by asking the patient after one week.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |